American Airlines is facing a sharply deteriorating tape — down 7.2% on the week and 15.2% over the past month — while short sellers materially step up their conviction.
Short interest has climbed nearly 20% in a single week, reaching 10.8% of the free float as of September 1. That's the fastest weekly build in the past 30-day window visible in the data, with shares short jumping from roughly 60 million to 71.6 million over just the past two weeks. The move stands out even within a sector-wide selloff: close peer UAL fell 10.9% on the week and DAL slid 8.7%, suggesting industry-level pressure is real — but the short-side acceleration in AAL specifically implies something more idiosyncratic is attracting bearish conviction. Borrow costs remain low at 0.44%, and the lending pool is comfortable with availability near 869% of outstanding short interest — far from squeeze territory. This is an informed, freely-entered short position, not a trapped one.
Options positioning is structurally defensive but not alarmed. The put/call ratio runs at 1.51, barely above its 20-day average of 1.50, putting the z-score at just 0.5. Compared to the 52-week high PCR of 2.41, the current reading is actually moderate — options traders are not pressing the panic button even as the stock falls and shorts build. That disconnect is worth noting: short sellers are growing more aggressive while options hedgers are not adding to protection. One reading is that the short side is deliberate and directional rather than reactive.
The Street tells a mixed story, but the direction of travel is clearly downward on targets. Most analysts maintained ratings after Q2 results in late July but trimmed price targets — Citi cut to $19 from $22, Goldman lowered to $13 from $15 (maintaining its Sell), and UBS kept its Buy but marked the target down to $18 from $21. The most recent move came August 24, when TD Cowen slashed its target from $24 to $16 while holding a Buy. The mean target of $18.50 implies roughly 43% upside from the current $12.95 close — but with Goldman's Sell at $13 essentially marking the stock fairly valued today and the analyst recommendation difference factor scoring in just the 5th percentile, the bull-bear divide is unusually wide. EPS surprise ranks in the 94th percentile and 90-day earnings momentum is in the 98th, suggesting the underlying earnings picture is actually robust — the tension is between strong earnings revisions and a stock priced for distress.
PRIMECAP Management is the standout among institutional holders, having grown its position to 10.7% of shares (roughly 70.7 million shares) with a large addition of 21.7 million shares in the most recent filing period. The balance between a major long-only manager building a 10%-plus stake and short sellers adding aggressively to an 11%-of-float position creates an unusual tug-of-war in the stock. On the insider side, Vice Chair Stephen Johnson and SVP Angela Owens both made open-market sales in late July at around $15.25–$15.29 — discretionary sales, not 10b5-1 plans, and at prices roughly 18% above today's close. Net insider disposals totalled approximately $1.5 million over the past 90 days. None of the trades were enormous in dollar terms, but the absence of any buying from insiders while the stock retreats to multi-month lows is a notable gap.
The next earnings print is scheduled for October 21. Historically the recent pattern has been mixed: Q2 results in July produced a 2.1% one-day decline followed by a 4.3% five-day recovery, while the prior quarter's print saw an 11.3% one-day drop. With short interest now at one of its highest levels of the year, how the borrow market and short positioning evolve into that date — and whether the sector-wide pressure stabilises or deepens — will define whether the current bearish setup has room to build further or runs into a covering event.
See the live data behind this article on ORTEX.
Open AAL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
